Phytoterapy combined with prostate chronic inflammatory diseases and their complications in persons with diabetes mellitus
##plugins.themes.bootstrap3.article.main##
Abstract
##plugins.themes.bootstrap3.article.details##
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Marchal de Calvi Ch.-J. Recherches sur les accidents diabétiques et essai d’une théorie générale de diabète. Asselin und Labé. 1864. – 658 p.
Ellenberg M., Weber H. Bladder decompensation correlates with diabetic neuropathy. JAMA. 1966; 197(7): 39.
Ellenberg M., Weber H. The incipient asymptomatic diabetic bladder. Diabetes 1967; 16(5): 331–335.
Dedov I.I., Kurbatov D.G. i soavt. Urologicheskie i andrologicheskie zabolevanija pri saharnom diabete // Urologija. – 2009. – № 4. – S. 74–79.
Kuz'min I.V., Shabudina N.O. Jepidemiologija i faktory riska razvitija narushenij mocheispuskanija u bol'nyh saharnym diabetom // Urologija, 2014. – № 6. – S. 114–118.
Hampel C. Gillitzer R., Pahernik S. et al. Diabetes mellitus and bladder function. What should be considered? Urol. 2003; 42 (12): P. 1556–1563.
Brown J.S. Diabetic cystopathy – what does it mean? Urol. 2009; 181(1): P. 13–14.
Ficarra V, Rossanese M, Zazzara M et. al. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy //Curr Urol Rep. 2014. Dec;15(12): P. 463.
Naber K., Weidner W. Chronic prostatitis: an infectious disease? // J Antimicrob. Chemother. – 2000. – V. 46. – P. 157–161.
De Marzo A.M. Pathological and molecular mechanisms of prostate cancerogenesis: implications for diagnosis, prevention and treatment // J Cell Biochem. – 2004. –V. 91. – P. 459–477.
Karakiewicz P.I., Benayoun S., Begin L.R. et al. Chronic inflammation is negatively associated with prostate cancer and high grade prostatic intraepithelial neoplasia on needle biopsy // Int J Clin Pract. – 2007. – V. 71. – P. 425–430.
Kramer G., Mitteregger D., Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? // Eur Urol. – 2007. – V. 51. – P. 1202–1216.
Elkahwaji J.E., Zhong W., Bushman W. Chronic bacterial infection and inflammation incite reactive hyperplasia in a mouse model of chronic prostatitis // Prostate. – 2007. – V. 67. – P. 14–21.
Ueda T., Yoshimura N., Yoshida O. Diabetic cystopathy: relationship to autonomic neuropathy detected by sympathetic skin response. J Urol. (Baltimore). 1997; 157(2): 580–584.
Yu H.J., Lee W.C., Liu S.P. et al. Unrecognized voiding difficulty in female type 2 diabetic patients in the diabetes clinic: a prospective case-control study. Diabetes Care. 2004; 27: 988–989.
Frimodt-Moller C. Diabetic cystopathy. I: A clinical study of the frequency of bladder dysfunction in diabetics. Dan. Med. Bull. 1976; 23: 267–278.
Liao Y., Li C., Chang L. et al. The time since the diagnosis of diabetes might be linked to lower urinary tract symptoms. Neurourol Urodyn. 2013; 32 (6): 700–701.
Sasaki K., Yoshimura N., Chancellor M.B. Implications of diabetes mellitus in urology. Urol. Clin. North. Am. 2003; 30: 1–12.
Frimodt-Moller C. Diabetic cystopathy: epidemiology and related disorders. Ann. Intern. Med. 1980; 92: 318–321.
Kolesnikova L.I., Darenskaya M.A., Grebenkina L.A. et al. Lipid peroxidation and protection in patients with diabetes mellitus type i during reproductive system development. Journal of Diabetes & Metabolism. 2013;4 (6):37.
Nelson W.G., De Marzo A.M., Isaacs W.B. Prostate cancer //N. Engl. J. Med. – 2003. – V. 349. – P. 366–381.
Tomas D., Krušlin B., Rogatsch H., et al. Different types of atrophy in the prostate with and without adenocarcinoma // Eur. Urol. – 2007. – V. 51. – P. 98–104.
Naber K., Weidner W. Chronic prostatitis: an infectious disease? // J Antimicrob. Chemother. – 2000. –V. 46. – P. 157–161.
De Marzo A.M., Platz E.A., Sutcliffe S. et al. Inflammation in prostate carcinogenesis // Nat Rev. – 2007. – V. 7. – P. 256–269.
Ko E.Y., Sabanegh E.S.Jr., Agarwal A. Male infertility testing: reactive oxygen species and antioxidant capacity. Fertil. Steril. 2014; 102:1518–1527.
Joffe M. What has happened to human fertility. Hum. Reproduction. 2010; 25:295–307.
Kolesnikova L.I., Kurashova N.A., Dolgih M.I. i soavt. Primenenie integral'nogo pokazatelja dlja ocenki okislitel'nogo stressa u muzhchin s patospermiej i saharnym diabetom 1-go tipa // Urologija. – 2015. – № 4. – S. 71–74.
Zagarskih E.Ju., Labygina A.V., Kurashova N.A. Opyt lechenija normogonadotropnogo besplodija. Urologija. 2014;5:87–89.
Gorpinchenko I.I., Romanjuk M.G., Aksenov P.V., Kornienko A.M. Svechi Pravenor – novoe slovo v fitoprofilaktike zabolevanij predstatel'noj zhelezy // Zdorov'e muzhchiny, 2015. – № 3 (54). – S. 65–70.
Gorpinchenko I.I. Gurzhenko Ju.M., Spiridonenko V.V. Teoretichne obg'runtuvannja efektivnosti fitoterapii' u cholovikiv iz zapal'nimi zahvorjuvannjami peredmihurovoi' zalozi // Zdorov'e muzhchiny, 2015. – № 4 (55). – S. 45–49.
Chua T., Eise N.T, Simpson J.S., Ventura S. Pharmacological characterization and chemical fractionation of a liposterolic extract of saw palmetto (Serenoa repens): effects on rat prostate contractility // J Ethnopharmacol. 2014 Mar 14; V. 152 (2): P. 283–91.
Forray C., Bard J.A., Wetzel J.M. et al. The b1adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human b1s subtype. Mol. Pharmacol. 1994; 45 (4): 703–708.
Goldstraw M.A., Fitzpatrick J.M., Kirby R.S. What is the role of inflammation in the pathogenesis of prostate cancer // BJU Int. – 2007. – V. 15. – P. 1–2.
Martinon F., Petrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome // Nature. – 2006. – V. 440. – P. 237–241.
Di Silverio F, Gentile V., De Matteis A. et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis // Eur Urol. – 2003. – V. 43. – P. 164–175.
Bostanci Y., Kazzazi A., Momtahen S., Laze J., Djavan V. Correlation between benign prostatic hyperplasia and inflammation // BENIGN PROSTATIC HYPERPLASIA. 2013 – Vol. 23 (1). – R. 5–10.
Di Silverio F., Bosman C., Salvatori M. et al. Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) // Eur. Urol. – 2005. – V. 47 – P. 72–79.
De Marzo A.M. Pathological and molecular mechanisms of prostate cancerogenesis: implications for diagnosis, prevention and treatment // J Cell Biochem. – 2004. – V. 91. – P. 459–477.
Wu YN, Liao CH, Chen KC, Liu SP, Chiang HS. Effect of Ginkgo biloba Extract (EGb-761) on Recovery of Erectile Dysfunction in Bilateral Cavernous Nerve Injury Rat Model. Urology. 2015 May; 85 (5): 1214.7–15.
Urtica.Therapeutic and nutritional aspects of stinging nettles”. Edited by Gulsel M. Kavalali. Series: “Medicinal and Aromatic Plants – Industrial Profiles. 2003.
Dreikorn K., Richter R. Conservative nonhormonal treatment of patients with benign prostatic hyperplasia, in Ackerman R., and Schroeder F.H. (Eds): New Developments in Biosciences 5, Prostatic Hyperplasia. Brlin, New York, Walter de Gruyter &CO., 1989, pp. 109–131.
Marwick C. Growing use of medicinal botanicals forces assessment by drug regulators. JAMA 1995; 273: 607–9.
Dreikorn K., Borkowski A., Braeckman J., et al. Other Medical Therapies. Proceedings of the Fourth International Consultation on Benign Prostatic Hyperplasia (BPH). Paris, Scientific Communication International Limited, 1997.
Lowe F.C., Ku J.C. Phytotherapy in treatment of benign prostatic hyperplasia: A critical review // Urology, 1996; 48:12.
Ahmed H.H., Fayez M., Diab A., El-Badry A.A. Effect of beta-sitosterol alone and in combination with naloxone or L-dopa on serum prolactin, luteinizing hormone and follicle stimulating hormone of female ovariectomised rate // J. Egypt Vet. Med. Ass. 1987; 47: 453–60.
Safarinejad M.R. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study // J Herb Pharmacother. 2005;5(4):1–11.
Zeng H., Wu M., Botnen J.H. Methylselenol, a selenium metabolite, induces cell cycle arrest in G1 phase and apoptosis via the extracellular-regulated kinase 1/2 pathway and other cancer signaling genes F //Journal of Nutrition, 2009, 139 (9), 1613–1618.
Zeng H., Briske-Anderson M., Wu M., Moyer M.R. Methylselenol, a selenium metabolite, plays common and different roles in cancerous colon HCT116 cell and noncancerous NCM460 colon cell proliferation // Nutrition and Cancer, 2012. 64, 128–135.
Chopik V.I., Dudchenko L.G, Krasnova A.N. Dikorastushhie poleznye rastenija Ukrainy. Spravochnik. – K.: Naukova dumka, 1983. – 400 s.
Rastitel'nye resursy SSSR. Cvetkovye rastenija, ih himicheskij sostav, ispol'zovanie. Semejstva Hedrangeaceae – Haloragaceae. – L., 1987.
Pepenin V.R., Spiridonenko V.V., Pepenin S.V. Vozmozhnosti jekstrakta jakorcev cteljushhihsja v terapii hronicheskogo prostatita i ego oslozhnenij // Zdorov'e muzhchiny. – 2009. – № 3. – S. 57–59.
Gorpinchenko I.I., Imshineckaja L.P., Gurzhenko Ju.N. Issledovanie jeffektivnosti preparata Tribestan dlja negormonal'nogo lechenija vtorichnogo gipogonadizma u muzhchin // Zdorov'e muzhchiny, 2011. – №3 (38). – S. 1–3.
Chhatre S., Nesari T., Somani G. et al. Phytopharmacological overview of Tribulus terrestris //Pharmacogn Rev. 2014 Jan-Jun; 8(15): 45–51.